

Ongoing monitoring during methylphenidate (MPH)[†] treatment

As outlined in the Product Information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored:

- Blood pressure and heart rate should be recorded at each adjustment of dose and then at least every 6 months.
- In children, height, weight and appetite should be recorded at least 6-monthly with maintenance of a growth chart.
- Development of *de novo*, or worsening of pre-existing, psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit.

Patient name:

Date of birth:

Age:

Gender:

	Baseline	Subsequent appointments								
Date of assessment										
Reason of assessment										
Blood pressure*										
Heart rate*										
Body weight (kg)**										
Height (cm)**										
Appetite**										
Psychiatric symptoms										

[†]This checklist is designed to support you in the monitoring of patients with Ritalin 10 or Artige 10 or Ritalin LA treatment.

*Blood pressure and heart rate should be recorded at each adjustment of dose and then at least every 6 months

**In children, height, weight and appetite should be recorded at least 6-monthly with maintenance of a growth chart

Ritalin® 10 & Ritalin® LA: PBS and Product Information

PBS Information: Ritalin 10®. Authority required.

Use in attention deficit hyperactivity disorder, in accordance with State/Territory law.

Ritalin LA®. Authority required. Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours.

DRUG DEPENDENCE:

Ritalin should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow up.



PRIT0625

For healthcare professionals only. Please review full Product Information before prescribing. Scan QR code for full Ritalin® and Ritalin® LA Product Information

Alternately, please contact Medical Information at 1 800 671 203 or visit: <https://www.novartis.com.au/products/healthcare-professionals/products> to access the full Product Information

Artige®: PBS and Product Information

PBS Information: Artige®. Authority required.

Use in attention deficit hyperactivity disorder, in accordance with State/Territory law.

DRUG DEPENDENCE:

Artige should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow up.



PART0625

For healthcare professionals only. Please review full Product Information before prescribing. Scan QR code for full Artige Product Information

Alternately, please contact Medical Information at 1 800 671 203 or visit: <https://www.novartis.com.au/products/healthcare-professionals/products> to access the full Product Information

For the most up-to-date Product Information go to <https://www.novartis.com.au/products/healthcare-professionals/products>

®Registered trademark. ©2025 Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160.

54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555.

For medical enquiries please contact 1800 671 203 or medinfo.phauno@novartis.com.

AU-28550. Date of preparation: May 2025.